Recordati S.p.A. REC
MIL · Italy · Health Technology
€52.55-0.10 (-0.19%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
RECORDATI ANNOUNCES THE WINNER OF THE 12TH EDITION OF THE ARRIGO RECORDATI PRIZE FOR SCIENTIFIC RESEARCH The 2026 Award, open to early career investigators from around the world, was dedicated to advancing research in paediatric oncology, focused on sarcomasPaediatric sarcomas are among the leading causes of cancer-related death in children, yet there has been little innovation in treatment progress over the past 40 yearsDr. Laura Broutier has been awarded the €250,000 research grant for her DIS
Recordati SpA (RCDTF) reports robust H1 2026 results with revenue up 6.6% and EBITDA growth of 8.8%, fueled by a 17.1% surge in rare disease revenues, while specialty and primary care faces headwinds.
As European markets experience gains, buoyed by hopes of de-escalation in the Middle East, the economic landscape remains challenging with revised growth forecasts and rising inflation concerns. In this environment, identifying undervalued stocks can be crucial for investors looking to capitalize on potential market inefficiencies and long-term value opportunities.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.